PRAF2 acts as a "gatekeeper" for chemokine receptors like CCR5, retaining them in the ER via transmembrane domain interactions . This contrasts with CD4, which promotes CCR5 plasma membrane export . In vesicular traffic, PRAF2 interacts with Rab GTPases and modulates ER/Golgi trafficking pathways .
PRAF2 binds anti-apoptotic proteins Bcl-xL and Bcl-2 through their transmembrane domains, counteracting their survival signals . Overexpression induces apoptosis by triggering Bax mitochondrial translocation and caspase activation, which is inhibited by wild-type Bcl-xL but not its transmembrane domain-deleted mutant .
PRAF2 binds HPV E5 oncoprotein, with amino acids 135–160 critical for interaction . This interaction may disrupt viral lifecycle processes, such as E1^E4 expression in organotypic rafts .
Recombinant bovine PRAF2 is utilized in:
Cell-Surface Protein Localization Studies: BRET assays to monitor CCR5 retention in the ER .
Apoptosis Pathway Analysis: Co-immunoprecipitation (Co-IP) and PARP cleavage assays to assess pro-apoptotic activity .
Viral Oncology Research: Proximity-dependent biotinylation (BioID) to map interactomes with HPV E5 .
PRAF2 overexpression is linked to poor prognosis in hepatocellular carcinoma, glioblastoma, and neuroblastoma . In cervical cancer models, its knockdown reduces colony formation and migration, suggesting oncogenic potential . Conversely, its pro-apoptotic activity in normal cells highlights therapeutic potential for targeting apoptosis-resistant cancers .
Expression Systems: Recombinant PRAF2 is produced in S2 insect cells or mammalian systems (e.g., HEK293) .
Antibodies: Polyclonal rabbit antibodies (e.g., Sigma-Aldrich ABC95) target native and recombinant PRAF2 for Western blot and immunohistochemistry .
Species Cross-Reactivity: Bovine PRAF2 antibodies show predicted reactivity with human, mouse, and rat proteins .